Anti-CCR5 antibodies and methods of use therefor
AssigneeMillennium Pharmaceuticals, Inc.
InventorsLijun Wu, Charles R. Mackay
Life of this patent
Estimating the term…
Abstract
The present invention relates to an antibody or functional portion thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 5 protein (CKR-5 or CCR5) or portion of the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR5 with a ligand thereof. Another aspect of the invention relates to a method of inhibiting HIV infection of a cell which expresses a mammalian CCR5 or portion thereof using the antibodies described herein. Also encompassed by the present invention are methods of treating or preventing HIV in a patient.
Claims74
An antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein.
An antibody having specificity for a mammalian CC-chemokine receptor 5 protein, wherein the antibody inhibits binding of a ligand to the receptor and inhibits function associated with binding of the ligand to the receptor.
A method of inhibiting the interaction of a cell bearing mammalian CC-chemokine receptor 5 protein with a ligand thereof, comprising contacting said cell with an effective amount of an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein.
A method of inhibiting HIV infection of a cell, comprising contacting a cell with an effective amount of an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein.
A method of treating HIV in a patient, comprising administering to the patient an effective amount of an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein.
A method of detecting expression of a mammalian CC-chemokine receptor 5 protein by a cell, comprising:
- a) contacting a composition comprising a cell to be tested with an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein under conditions appropriate for binding of said antibody or fragment thereto;
- and
- b) detecting binding of said antibody or fragment, wherein the binding of said antibody or fragment indicates the presence of said receptor on said cell.
A method of detecting the susceptibility of a mammal to HIV, comprising:
- a) contacting a sample to be tested with an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein under conditions appropriate for binding of said antibody or fragment thereto, wherein the sample comprises cells which express CCR5 in normal individuals;
- and
- b) detecting binding of said antibody or fragment,
- wherein the binding of said antibody or fragment indicates the level of receptor expressed by the cells, which correlates with the susceptibility of the mammal to HIV.
A method of determining the prognosis for an HIV-infected mammal, comprising:
- a) contacting a sample from the HIV-infected mammal to be tested with an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein under conditions appropriate for binding of said antibody or fragment thereto, wherein the sample comprises cells which express CCR5 in normal individuals;
- and
- b) detecting binding of said antibody or fragment,
- wherein the binding of said antibody or fragment indicates the level of receptor expressed by the cells, which correlates with a poorer prognosis for the HIV-infected mammal.
A method of inhibiting HIV infection in a patient, comprising administering to the patient an effective amount of an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein.
A method of inhibiting leukocyte trafficking in a patient, comprising administering to the patient an effective amount of an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein.
A method of inhibiting the interaction of a cell bearing mammalian CC-chemokine receptor 5 protein with a chemokine, comprising contacting said cell with an effective amount of an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein.
A method of inhibiting a function associated with binding of a chemokine to a mammalian CC-chemokine receptor 5 protein or antigen-binding fragment thereof, comprising contacting a composition comprising the protein with an effective amount of an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein.
The hybridoma cell line deposited under ATCC Accession No. HB-12366.
The hybridoma cell line deposited under ATCC Accession No. HB-12222.
A test kit for use in detecting the presence of a mammalian CC-chemokine receptor 5 protein in a biological sample comprising
- a) an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein;
- and
- b) one or more ancillary reagents suitable for detecting the presence of a complex between said antibody or antigen-binding fragment thereof and said protein.
A bispecific antibody or antigen-binding fragment thereof having an epitopic specificity which is the same as or similar to that of 2D7 and 5C7.
A bispecific antibody or antigen-binding fragment thereof which binds a second extracellular loop or portion thereof and an amino terminal region or portion thereof of a mammalian CC-chemokine receptor 5 protein.
A method of detecting or identifying an agent which binds a mammalian CC-chemokine receptor 5 protein or ligand binding variant thereof, comprising combining
- an agent to be tested;
- an antibody or antigen-binding fragment selected from the group consisting of monoclonal antibody 2D7, an antibody having an epitopic specificity which is the same as or similar to that of 2D7, and antigen-binding fragments thereof;
- and
- a composition comprising a mammalian CC-chemokine receptor 5 protein or a ligand binding variant thereof,
- under conditions suitable for binding of said antibody or antigen-binding fragment thereto, and
- detecting or measuring binding of said antibody or fragment to said mammalian CC-chemokine receptor 5 protein or ligand binding variant.
A method of detecting or identifying an agent which binds a mammalian CC-chemokine receptor 5 protein or a ligand binding variant thereof comprising combining
- an agent to be tested;
- an antibody or antigen binding fragment selected from the group consisting of monoclonal antibody 2D7, an antibody having an epitopic specificity which is the same as or similar to that of 2D7, and antigen-binding fragments thereof;
- and
- a cell bearing a mammalian CC-chemokine receptor 5 protein or a ligand binding variant thereof,
- under conditions suitable for binding of said antibody or antigen-binding fragment thereto, and
- detecting or measuring binding of said antibody or fragment to said mammalian CC-chemokine receptor 5 protein or variant.
A method of detecting a mammalian CC-chemokine receptor 5 protein, comprising:
- a) contacting a sample to be tested with an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein under conditions appropriate for specific binding of said antibody or antigen-binding fragment thereto;
- and
- b) detecting or measuring binding of said antibody or antigen-binding fragment thereof, wherein the binding of said antibody or antigen-binding fragment thereof to material in said sample is indicative of the presence of a mammalian CC-chemokine receptor 5 protein in said sample.
A method of detecting the susceptibility of a mammal to HIV, comprising:
- a) contacting a sample to be tested with an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein under conditions appropriate for binding of said antibody or antigen-binding fragment thereto;
- and
- b) detecting or measuring binding of said antibody or antigen-binding fragment thereof,
- wherein the binding of said antibody or antigen-binding fragment thereof to material in said sample is indicative of the level of a mammalian CC-chemokine receptor 5 protein in said sample, which is correlated with the susceptibility of the mammal to HIV.
A method of inhibiting a function associated with binding of a chemokine to the CC-chemokine receptor 5 protein in a mammal in need thereof, comprising administering an effective amount of an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 5 protein.
A method of treating a CC-chemokine receptor 5-mediated condition in a patient, comprising administering to the patient an effective amount of an antibody or antigen-binding fragment thereof which binds to mammalian CC-chemokine receptor 5.
Dependencies are inferred from the claim text.